72 related articles for article (PubMed ID: 22032858)
1. [The OASIS study: therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies].
Luque-Ramírez M; Carreño A; Alvarez Escolá C; del Pozo Picó C; Varela da Costa C; Fajardo Montañana C; Gilabert M; Webb S;
Endocrinol Nutr; 2011 Nov; 58(9):478-86. PubMed ID: 22032858
[TBL] [Abstract][Full Text] [Related]
2. The choice of therapy in acromegaly: results of treatment at a tertiary care hospital.
Isidro ML; Castro JA; Penín M; Armenta J; Cordido F
Neuro Endocrinol Lett; 2008 Dec; 29(6):1038-44. PubMed ID: 19112390
[TBL] [Abstract][Full Text] [Related]
3. Acromegaly: presentation, morbidity and treatment outcomes at a single centre.
Anagnostis P; Efstathiadou ZA; Polyzos SA; Adamidou F; Slavakis A; Sapranidis M; Litsas ID; Katergari S; Selalmatzidou D; Kita M
Int J Clin Pract; 2011 Aug; 65(8):896-902. PubMed ID: 21679284
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes and mortality of 94 patients with acromegaly.
Trepp R; Stettler C; Zwahlen M; Seiler R; Diem P; Christ ER
Acta Neurochir (Wien); 2005 Mar; 147(3):243-51; discussion 250-1. PubMed ID: 15627919
[TBL] [Abstract][Full Text] [Related]
5. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of acromegaly in Aarhus University Hospital. A retrospective investigation of the period from 1994 to 2004].
Madsen M; Matthiesen EB; Poulsen PL; Weeke J; Astrup J; Jørgensen JO
Ugeskr Laeger; 2007 Mar; 169(10):907-10. PubMed ID: 17359734
[TBL] [Abstract][Full Text] [Related]
7. A follow-up of 130 patients with acromegaly in a single centre.
Bolanowski M; Zatonska K; Kaluzny M; Zielinski G; Bednarek-Tupikowska G; Bohdanowicz-Pawlak A; Daroszewski J; Szymczak J; Podgorski JK
Neuro Endocrinol Lett; 2006 Dec; 27(6):828-32. PubMed ID: 17187024
[TBL] [Abstract][Full Text] [Related]
8. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
9. [Acromegaly: multifaceted clinical presentation of a rare disease of the elderly. Report of two cases with long-term follow-up].
Foppiani L; Del Monte P; Ruelle A; Marugo A; Bernasconi D
Recenti Prog Med; 2006 Apr; 97(4):200-4. PubMed ID: 16729489
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of acromegaly. Results in 56 patients].
del Pozo C; Webb SM; Oliver B; Tresserras P; de Leiva A
Med Clin (Barc); 1990 Jan; 94(3):85-7. PubMed ID: 2314144
[TBL] [Abstract][Full Text] [Related]
11. Adolescent acromegaly and decreased arterial distensibility despite successful treatment.
Bassareo PP; Marras AR; Mercuro G
Clin Endocrinol (Oxf); 2012 Jul; 77(1):79-85. PubMed ID: 22182355
[TBL] [Abstract][Full Text] [Related]
12. Gamma-knife surgery is effective in normalising plasma insulin-like growth factor I in patients with acromegaly.
Gutt B; Wowra B; Alexandrov R; Uhl E; Schaaf L; Stalla GK; Schopohl J
Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):219-24. PubMed ID: 15891958
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of octreotide LAR as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: predictive factors of tumor and biochemical response.
Luque-Ramírez M; Portoles GR; Varela C; Albero R; Halperin I; Moreiro J; Soto A; Casamitjana R;
Horm Metab Res; 2010 Jan; 42(1):38-44. PubMed ID: 19798622
[TBL] [Abstract][Full Text] [Related]
15. [Acromegaly].
Morange I; Jaquet P
Rev Prat; 1996 Jun; 46(12):1482-5. PubMed ID: 8881161
[TBL] [Abstract][Full Text] [Related]
16. Therapy for the syndromes of GH excess.
Arosio M; Cannavò S; Epaminonda P; Ronchi C; Chiodini I; Adda G
J Endocrinol Invest; 2003; 26(10 Suppl):36-43. PubMed ID: 15497658
[TBL] [Abstract][Full Text] [Related]
17. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
Minniti G; Jaffrain-Rea ML; Osti M; Esposito V; Santoro A; Solda F; Gargiulo P; Tamburrano G; Enrici RM
Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy or surgery as primary treatment for acromegaly?
Ferone D; Colao A; van der Lely AJ; Lamberts SW
Drugs Aging; 2000 Aug; 17(2):81-92. PubMed ID: 10984197
[TBL] [Abstract][Full Text] [Related]
19. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
20. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
